Who Is Eligible for Measura Testing?

For physicians

Selection criteria

Two questions, answered separately: which patients should be assessed, and which assessments should each of them have.

Question one: who

The population criteria are deliberately broad, because the yield in this population is high and the assessments are non-invasive.

CriterionRationale
Age over 50 with a cardiovascular risk factorVascular and small-fiber change is prevalent and silent in this group
Age over 70, unconditionallyVestibular dysfunction and peripheral artery disease prevalence both rise steeply with age
HypertensionSmall-vessel damage and impaired autonomic blood pressure control coexist
Overweight or raised abdominal girthMetabolic health prevalence falls sharply with adiposity
Current or former tobacco useThe strongest single association with peripheral artery disease
Diabetes or impaired glucose toleranceSmall-fiber injury begins during the compensating phase
Any one criterion is sufficient.

Question two: which assessments

Match the panel to the presenting question rather than running everything.

Numb, burning or insensate feet

Sudomotor testing, vascular study with toe-brachial index, laboratory panel including glycemic and B12 markers. Sudomotor testing

Claudication or reduced walking distance

Ankle-brachial and toe-brachial index, pulse volume recording, arterial stiffness. Ankle-brachial index

Unsteadiness, dizziness or a fall

Vestibular and oculomotor battery, orthostatic and autonomic testing, sensory assessment, cognitive screen. Balance testing

Fatigue, exercise intolerance, palpitations

Heart rate variability, cardiac autonomic reflex tests, pulse waveform analysis. Heart rate variability

Weight that will not move, or a stalled program

Measured resting energy expenditure and respiratory quotient, body composition, insulin and glycemic markers. Indirect calorimetry

Asymptomatic, in the risk group

The core panel: vascular study, sudomotor, autonomic, body composition, laboratory. The full library

Who should not be assessed

  • Anyone in an acute presentation. Chest pain, acute limb ischemia, sudden neurological deficit or acute infection needs emergency care, not a diagnostic appointment.
  • Low-risk asymptomatic adults under 50. The yield does not justify it.
  • Patients for whom the result cannot change management — because of comorbidity, prognosis or preference.
  • Patients with implanted electrical devices, for the bioimpedance component specifically. The remainder of the suite proceeds.

Repeat intervals

Set the interval from the finding, not from the calendar. A normal study in a risk-group patient usually repeats annually. A borderline finding repeats sooner, under controlled conditions, before anything is concluded from it. An abnormal finding under active management repeats at whatever interval makes the intervention assessable — often three to six months for metabolic measures, longer for structural vascular ones.

For patients: the same subject written for the person having the assessment is at who should be tested.

Talk to someone about testing

Tell us what you are trying to find out and we will explain which Measura assessments answer that question, what each one involves, and how the results are reviewed with a clinician.

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Call us with clinical detail.

Common questions

Should asymptomatic patients be assessed at all?

In the defined risk group, yes — that is where the silent findings are. Who should have this testing.

How do I choose between sudomotor testing and a nerve conduction study?

They measure different fiber populations; the presenting symptom usually tells you which. Small-fiber versus large-fiber neuropathy.

What repeat interval should I use?

Set it from the finding and from what is being changed. Repeat intervals.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed .